Name (Synonyms) | Correlation | |
---|---|---|
drug732 | Sarilumab Wiki | 0.29 |
drug82 | Azithromycin Wiki | 0.15 |
drug360 | Hydroxychloroquine Wiki | 0.09 |
drug616 | Placebo Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D055371 | Acute Lung Injury NIH | 0.11 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.11 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
D011014 | Pneumonia NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
This is a study for patients who have respiratory infection caused by SARS-CoV-2 that have not gotten better. Because there is no standard treatment for this infection, patients are being asked to volunteer for a gene transfer research study using mesenchymal stem cells (MSCs). Stem cells are cells that do not yet have a specific function in the body. Mesenchymal stem cells (MSCs) are a type of stem cell that can be grown from bone marrow (the spongy tissue inside of bones). Stem cells can develop into other types of more mature (specific) cells, such as blood and muscle cells. The purpose of this study is to see if MSCs can help to treat respiratory infections caused by SARS-CoV-2.
Description: Incidence of unexpected adverse events within 28 days following infusion of MSCs. Adverse events are graded by CTCAE version 5.
Measure: Incidence of unexpected adverse events Time: 28 days post cell infusionDescription: Proportion of patients with improved oxygenation, defined as oxygen saturation >=93% on room air or no more than 5L of supplemental oxygen.
Measure: Improved oxygen saturations ≥93% Time: Within 7 days of cell infusionDescription: Decrease in oxygen supplementation assessed by FiO2 % by non-invasive or invasive interventions from baseline to day 7.
Measure: Decrease in oxygen supplementation by non-invasive or invasive interventions Time: Within 7 days of cell infusionDescription: Frequency of patients who progress using mechanical ventilation or ECMO
Measure: Frequency of progression to mechanical ventilation or ECMO Time: 28 days post cell infusionDescription: Days on mechanical ventilation
Measure: Duration of mechanical ventilation Time: Days from time of intubation to extubation or date of death, whichever occurs first, assessed up to 28 days post-infusionDescription: Days of ICU stay
Measure: Duration of ICU stay Time: Days from admission to ICU to discharge from ICU or date of death, whichever occurs first, assessed up to 28 days post-infusionDescription: Days of hospital stay
Measure: Duration of hospital stay Time: Days from admission to hospital to discharge from hospital or date of death, whichever occurs first, assessed up to 28 days post-infusionDescription: Mortality rate from all causes at day 28
Measure: All-cause mortality at day 28 Time: 28 days post cell infusionNovel coronavirus COVID-19 has become a health emergency around the world. Since first patients were detected in Wuhan China, in December 2019, COVID-19 has spread quickly worldwide, being a severe threat to public health. Fever, dry cough, shortness of breath and breathing distress are the main characteristics of COVID-19 infection. Some patients develop overwhelming lung inflammation and acute respiratory failure, for which there is no specific therapy. Therefore, safe and effective treatment for COVID-19 pneumonia is utterly necessary, mainly in critical cases. Mesenchymal stem cells (MSCs) have been widely used in the immune-mediated inflammatory diseases. MSCs can regulate both innate and adaptive immunity by suppressing the proliferation, differentiation and activation of different cells. These immunomodulatory properties of MSCs support performance of the phase I/II, placebo- controlled, randomized MSCs for treatment of severe COVID-19 pneumonia.
Description: Index of therapy success to preserve Intensive Care Hospitalization space
Measure: Proportion of patients who have achieved withdrawal of invasive mechanical ventilation Time: 0-7 daysDescription: To measure global success
Measure: Rate of mortality Time: 28 daysDescription: Index based in the 4 most relevant symptoms and signs: fever, shortness of bread, %Hemoglobin Saturation and PaO2 / FiO2
Measure: Proportion of patients who have achieved clinical response Time: 0-7daysDescription: Evaluation of pneumonia changes
Measure: Proportion of patients who have achieved radiological responses Time: 0-28 daysDescription: Haemogram and cell subpopulations
Measure: Blood white cell counts and their subpopulations. Time: 0-180 daysDescription: Lymphocyte profiles, CD3, CD19, CD16+CD56, CD4/CD8, Tregs
Measure: Cellular markers of inflammation Time: 0-180 daysDescription: IL-10, IL-6, IP-10, TNF-alpha
Measure: Cytokines and chemokines in peripheral blood Time: 0-180 days